Health-related quality of life after chemotherapy with or without rituximab in primary central nervous system lymphoma patients: results from a randomised phase III study.

MLA

van der Meulen, M., et al. “Health-Related Quality of Life after Chemotherapy with or without Rituximab in Primary Central Nervous System Lymphoma Patients: Results from a Randomised Phase III Study.” Annals of Oncology : Official Journal of the European Society for Medical Oncology, vol. 31, no. 8, Aug. 2020, pp. 1046–55. EBSCOhost, https://doi.org/10.1016/j.annonc.2020.04.014.

APA

van der Meulen, M., Bakunina, K., Nijland, M., Minnema, M. C., Cull, G., Stevens, W. B. C., Baars, J. W., Mason, K. D., Beeker, A., Beijert, M., Taphoorn, M. J. B., van den Bent, M. J., Issa, S., Doorduijn, J. K., Bromberg, J. E. C., & Dirven, L. (2020). Health-related quality of life after chemotherapy with or without rituximab in primary central nervous system lymphoma patients: results from a randomised phase III study. Annals of Oncology : Official Journal of the European Society for Medical Oncology, 31(8), 1046–1055. https://doi.org/10.1016/j.annonc.2020.04.014

Chicago

van der Meulen, M, K Bakunina, M Nijland, M C Minnema, G Cull, W B C Stevens, J W Baars, et al. 2020. “Health-Related Quality of Life after Chemotherapy with or without Rituximab in Primary Central Nervous System Lymphoma Patients: Results from a Randomised Phase III Study.” Annals of Oncology : Official Journal of the European Society for Medical Oncology 31 (8): 1046–55. doi:10.1016/j.annonc.2020.04.014.